Adrenal Suppression With Chronic Topical Corticosteroid Use in Psoriasis Patients

被引:0
|
作者
Lam, Lisa H. [1 ]
Sugarman, Jeffrey L. [2 ]
机构
[1] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA
关键词
ATOPIC-DERMATITIS; AXIS SUPPRESSION; INSUFFICIENCY; THERAPY;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background:Topical corticosteroids (TCS) are typically used for extended periods of time for chrOnic skin conditions, including psoriasis. Chronic TCS use may result in side effects similar to those of systemic corticosteroids. Patients may have subclinical adrenal suppression and be unaware of their risk in the case of serious trauma. Objective: The objective of this study was to investigate the real world effects of chronic TCS use and its effects on adrenal suppression in a chronic disease such as psoriasis. Materials:This retrospective study utilized data from screening visits of a psoriasis clinical trial in which subjects had been on chronicTCS. Results: In this study, subjects with moderate to severe psoriasis affecting 16-20% of total body surface area (BSA) and using high-potency TCS at screening had a lower post-cosyntropin cortisol level (18.83 mcg/dL) compared to those with moderate psoriasis involving 10-15% of total BSA and using lower potency TCS at screening (23.22 mcg/dL; P=0.03). Both subject groups had lower post-cosyntropin cortisol levels compared to normal, healthy adults (P<0.001 for both). Conclusion: This suggests that real world chronic use of high potencyTCS over a larger BSA may result in silent adrenal suppression.
引用
收藏
页码:945 / 948
页数:4
相关论文
共 50 条
  • [21] Iatrogenic adrenal gland suppression from use of a potent topical steroid
    Woo, WK
    McKenna, KE
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2003, 28 (06) : 672 - 673
  • [22] Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy
    Castela, E.
    Archier, E.
    Devaux, S.
    Gallini, A.
    Aractingi, S.
    Cribier, B.
    Jullien, D.
    Aubin, F.
    Bachelez, H.
    Joly, P.
    Le Maitre, M.
    Misery, L.
    Richard, M-A
    Paul, C.
    Ortonne, J. P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 : 47 - 51
  • [23] Hypertrichosis and topical corticosteroid use
    Ando, Yuya
    Ono, Sachiko
    Ono, Yosuke
    Miura, Yoshinori
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2022, 89 (02) : 71 - 72
  • [24] ADRENAL SUPPRESSION WITH TOPICAL HYDROCORTISONE BUTYRATE
    HENDRIKSE, JC
    MOOLENAAR, AJ
    DERMATOLOGICA, 1973, 147 (03): : 191 - 197
  • [25] TOPICAL CORTICOSTEROID-THERAPY IN PSORIASIS-VULGARIS
    TROZAK, DJ
    CUTIS, 1990, 46 (04): : 341 - 350
  • [26] TOPICAL CORTICOSTEROID-THERAPY FOR SEVERE SCALP PSORIASIS
    BRENEMAN, DL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (02) : 128 - 128
  • [27] RESULTS WITH A NEW TOPICAL CORTICOSTEROID IN 11 CASES OF PSORIASIS
    SIMONI, R
    GIORNALE ITALIANO DI DERMATOLOGIA MINERVA DERMATOLOGICA, 1977, 112 (01): : 65 - 75
  • [28] COMBINATION OF CYCLOSPORINE-A AND TOPICAL CORTICOSTEROID IN THE TREATMENT OF PSORIASIS
    GRIFFITHS, CEM
    POWLES, AV
    BAKER, BS
    FRY, L
    VALDIMARSSON, H
    TRANSPLANTATION PROCEEDINGS, 1988, 20 (03) : 50 - 52
  • [29] CLINICAL-TRIAL OF A TOPICAL CORTICOSTEROID IN CHILDREN WITH PSORIASIS
    LARREGUE, M
    GAZETTE MEDICALE DE FRANCE, 1977, 84 (03): : 255 - 258
  • [30] BONE FRACTURES CAUSED BY TOPICAL CORTICOSTEROID THERAPY FOR PSORIASIS
    Mitroi, G. G.
    Nicola, A.
    Pitru, A.
    Gheorghita, L.
    Bugala, N. M.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2023, 35 : S231 - S232